Christian Rommel

Executive Vice President, Global Head of Research & Development
Bayer Pharmaceuticals

Dr. Rommel has served as Executive Vice President, Global Head of Research & Development and a Member of the Executive Committee of Bayer Pharmaceuticals. From January 2014 to February 2021, Dr. Rommel served in various roles at Roche, most recently as Senior Vice President, Global Head of Oncology, Pharma Research and Early Development (pRED). Before that, Dr. Rommel worked at Amgen where he held roles such as Vice President of External Research and Development and Vice President, Research Oncology. Previously, he served as Chief Scientific Officer of Intellikine, a private biotech, from its inception to its acquisition by Takeda Pharmaceuticals. Earlier in his career, he worked at Merck-Serono in Geneva, Switzerland and as a scientist in the team of George Yancopoulos at Regeneron Pharmaceuticals, New York.

Beyond his role at Bayer, Dr. Rommel contributes to the Board of Directors for Vividion Therapeutics, Asklepios Bio, BlueRock Therapeutics, and CRISPR Therapeutics. He also
serves on the Board of Trustees for the Max Planck Institute for Molecular Genetics.

Dr. Rommel received his Ph.D. in molecular oncology from the Max Planck Institute in Berlin, Germany and the Institute of Medical Virology at the University of Zurich, Switzerland. He
is also a lecturer of biotechnology at the ETH Zurich, Switzerland.